Hepatitis C virus (HCV) infection remains a significant global health burden, contributing to progressive hepatic pathologies including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. While anti-hepatitis C peptides (AHCPs) have emerged as promising therapeutic candidates with distinct antiviral mechanisms, conventional wet-lab approaches for AHCP discovery face critical limitations in throughput and scalability. To overcome these constraints, we present Stack-Ahcp, an innovative stacked ensemble learning framework that synergistically integrates multiple machine learning algorithms through a meta-classification strategy. Our model achieves unprecedented predictive performance with 93.1% accuracy and an MCC of 0.863, substantially outperforming existing computational methods. Through comprehensive Shapley additive explanations (SHAP) analysis, we further delineate critical key intrinsic features and determinants governing AHCP bioactivity, enhancing the mechanistic interpretability of the prediction system. To facilitate translational applications, we have implemented an intuitive web interface (accessible at https://awi.cuhk.edu.cn/~biosequence/StackAHCP/index.php) that enables rapid screening and prioritization of candidate peptides. This resource is anticipated to streamline the identification of next-generation peptide therapeutics against HCV while reducing experimental validation costs. Beyond virology applications, our methodological framework establishes a paradigm for interpretable machine learning in biological sequence analysis, with potential adaptability to diverse multi-omics investigation scenarios.

RNA-protein interactions (RPIs) are essential for many biological functions and are associated with various diseases. Traditional methods for detecting RPIs are labor-intensive and costly, necessitating efficient computational methods. In this study, we proposed a novel sequence-based RPI prediction framework based on graph neural networks (GNNs) that addressed key limitations of existing methods, such as inadequate feature integration and negative sample construction. Our method represented RNAs and proteins as nodes in a unified interaction graph, enhancing the representation of RPI pairs through multi-feature fusion and employing self-supervised learning strategies for model training. The model's performance was validated through five-fold cross-validation, achieving accuracy of 0.880, 0.811, 0.950, 0.979, 0.910, and 0.924 on the RPI488, RPI369, RPI2241, RPI1807, RPI1446, and RPImerged datasets, respectively. Additionally, in cross-species generalization tests, our method outperformed existing methods, achieving an overall accuracy of 0.989 across 10 093 RPI pairs. Compared with other state-of-the-art RPI prediction methods, our approach demonstrates greater robustness and stability in RPI prediction, highlighting its potential for broad biological applications and large-scale RPI analysis.

Neuropeptides are essential signaling molecules produced in the nervous system that regulate diverse physiological processes and are closely implicated in the pathogenesis of neurodegenerative and neuropsychiatric disorders. Investigating neuropeptides contributes to a better understanding of their regulatory mechanisms and offers new insights into therapeutic strategies for related diseases. Therefore, accurate identification of neuropeptides is crucial for advancing biomedical research and drug development. Due to the high cost of experimental validation, various artificial intelligence methods have been developed for rapid neuropeptide identification. However, existing approaches often suffer from high computational resource consumption, slow processing speed, and poor deploy ability. Moreover, a user-friendly web server for practical application is still lacking. To this end, we propose MSKDNP, a neuropeptide prediction model based on a multi-stage knowledge distillation framework. With only 1.2% of the parameters, MSKDNP attains performance comparable to a fully fine-tuned protein language model while achieving state-of-the-art results in neuropeptide recognition. Moreover, MSKDNP provides favorable interpretability, facilitating biological understanding. A freely accessible web server is available at https://awi.cuhk.edu.cn/∼biosequence/MSKDNP/index.php.

Antiviral peptides (AVPs) have shown potential in inhibiting viral attachment, preventing viral fusion with host cells and disrupting viral replication due to their unique action mechanisms. They have now become a broad-spectrum, promising antiviral therapy. However, identifying effective AVPs is traditionally slow and costly. This study proposed a new two-stage computational framework for AVP identification. The first stage identifies AVPs from a wide range of peptides, and the second stage recognizes AVPs targeting specific families or viruses. This method integrates contrastive learning and multi-feature fusion strategy, focusing on sequence information and peptide characteristics, significantly enhancing predictive ability and interpretability. The evaluation results of the model show excellent performance, with accuracy of 0.9240 and Matthews correlation coefficient (MCC) score of 0.8482 on the non-AVP independent dataset, and accuracy of 0.9934 and MCC score of 0.9869 on the non-AMP independent dataset. Furthermore, our model can predict antiviral activities of AVPs against six key viral families (Coronaviridae, Retroviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae, Flaviviridae) and eight viruses (FIV, HCV, HIV, HPIV3, HSV1, INFVA, RSV, SARS-CoV). Finally, to facilitate user accessibility, we built a user-friendly web interface deployed at https://awi.cuhk.edu.cn/∼dbAMP/AVP/.

Cancer is a severe illness that significantly threatens human life and health. Anticancer peptides (ACPs) represent a promising therapeutic strategy for combating cancer. In silico methods enable rapid and accurate identification of ACPs without extensive human and material resources. This study proposes a two-stage computational framework called ACP-CapsPred, which can accurately identify ACPs and characterize their functional activities across different cancer types. ACP-CapsPred integrates a protein language model with evolutionary information and physicochemical properties of peptides, constructing a comprehensive profile of peptides. ACP-CapsPred employs a next-generation neural network, specifically capsule networks, to construct predictive models. Experimental results demonstrate that ACP-CapsPred exhibits satisfactory predictive capabilities in both stages, reaching state-of-the-art performance. In the first stage, ACP-CapsPred achieves accuracies of 80.25% and 95.71%, as well as F1-scores of 79.86% and 95.90%, on benchmark datasets Set 1 and Set 2, respectively. In the second stage, tasked with characterizing the functional activities of ACPs across five selected cancer types, ACP-CapsPred attains an average accuracy of 90.75% and an F1-score of 91.38%. Furthermore, ACP-CapsPred demonstrates excellent interpretability, revealing regions and residues associated with anticancer activity. Consequently, ACP-CapsPred presents a promising solution to expedite the development of ACPs and offers a novel perspective for other biological sequence analyses.

MicroRNA (miRNA)-target interaction (MTI) plays a substantial role in various cell activities, molecular regulations and physiological processes. Published biomedical literature is the carrier of high-confidence MTI knowledge. However, digging out this knowledge in an efficient manner from large-scale published articles remains challenging. To address this issue, we were motivated to construct a deep learning-based model. We applied the pre-trained language models to biomedical text to obtain the representation, and subsequently fed them into a deep neural network with gate mechanism layers and a fully connected layer for the extraction of MTI information sentences. Performances of the proposed models were evaluated using two datasets constructed on the basis of text data obtained from miRTarBase. The validation and test results revealed that incorporating both PubMedBERT and SciBERT for sentence level encoding with the long short-term memory (LSTM)-based deep neural network can yield an outstanding performance, with both F1 and accuracy being higher than 80% on validation data and test data. Additionally, the proposed deep learning method outperformed the following machine learning methods: random forest, support vector machine, logistic regression and bidirectional LSTM. This work would greatly facilitate studies on MTI analysis and regulations. It is anticipated that this work can assist in large-scale screening of miRNAs, thereby revealing their functional roles in various diseases, which is important for the development of highly specific drugs with fewer side effects. Source code and corpus are publicly available at https://github.com/qi29.

MOTIVATION: Antimicrobial peptides (AMPs) have the potential to inhibit multiple types of pathogens and to heal infections. Computational strategies can assist in characterizing novel AMPs from proteome or collections of synthetic sequences and discovering their functional abilities toward different microbial targets without intensive labor. RESULTS: Here, we present a deep learning-based method for computer-aided novel AMP discovery that utilizes the transformer neural network architecture with knowledge from natural language processing to extract peptide sequence information. We implemented the method for two AMP-related tasks: the first is to discriminate AMPs from other peptides, and the second task is identifying AMPs functional activities related to seven different targets (gram-negative bacteria, gram-positive bacteria, fungi, viruses, cancer cells, parasites and mammalian cell inhibition), which is a multi-label problem. In addition, asymmetric loss was adopted to resolve the intrinsic imbalance of dataset, particularly for the multi-label scenarios. The evaluation showed that our proposed scheme achieves the best performance for the first task (96.85% balanced accuracy) and has a more unbiased prediction for the second task (79.83% balanced accuracy averaged across all functional activities) when compared with that of strategies without imbalanced learning or deep learning. AVAILABILITY AND IMPLEMENTATION: The source code and data of this study are available at https://github.com/BiOmicsLab/TransImbAMP. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Antiviral peptide (AVP) is a kind of antimicrobial peptide (AMP) that has the potential ability to fight against virus infection. Machine learning-based prediction with a computational biology approach can facilitate the development of the novel therapeutic agents. In this study, we proposed a double-stage classification scheme, named AVPIden, for predicting the AVPs and their functional activities against different viruses. The first stage is to distinguish the AVP from a broad-spectrum peptide collection, including not only the regular peptides (non-AMP) but also the AMPs without antiviral functions (non-AVP). The second stage is responsible for characterizing one or more virus families or species that the AVP targets. Imbalanced learning is utilized to improve the performance of prediction. The AVPIden uses multiple descriptors to precisely demonstrate the peptide properties and adopts explainable machine learning strategies based on Shapley value to exploit how the descriptors impact the antiviral activities. Finally, the evaluation performance of the proposed model suggests its ability to predict the antivirus activities and their potential functions against six virus families (Coronaviridae, Retroviridae, Herpesviridae, Paramyxoviridae, Orthomyxoviridae, Flaviviridae) and eight kinds of virus (FIV, HCV, HIV, HPIV3, HSV1, INFVA, RSV, SARS-CoV). The AVPIden gives an option for reinforcing the development of AVPs with the computer-aided method and has been deployed at http://awi.cuhk.edu.cn/AVPIden/.